Kiora Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Fair Value Disclosures - Unobservable Level 3 Inputs (Details) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2022
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Change in fair value of contingent consideration	$ 0.2	$ 0.2
Discounted cash flow \| Payment discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business combination, measurement input, rate	0.134		0.147
Bayon \| Discounted cash flow \| Probability of success for payment \| Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business combination, measurement input, rate	0.17		0.17
Bayon \| Discounted cash flow \| Probability of success for payment \| Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business combination, measurement input, rate	0.67		0.67
Panoptes \| Discounted cash flow \| Probability of success for payment \| Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business combination, measurement input, rate	0.17		0.17
Panoptes \| Discounted cash flow \| Probability of success for payment \| Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business combination, measurement input, rate	0.36		0.36
Jade \| Discounted cash flow \| Probability of success for payment
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business combination, measurement input, rate	0.56		0.56